Nucleoside transporter-mediated uptake and release of [3H]l-adenosine in DDT1 MF-2 smooth muscle cells
Identifieur interne : 003D07 ( Main/Exploration ); précédent : 003D06; suivant : 003D08Nucleoside transporter-mediated uptake and release of [3H]l-adenosine in DDT1 MF-2 smooth muscle cells
Auteurs : Irene O. Foga [Canada] ; Jonathan D. Geiger [Canada] ; Fiona E. Parkinson [Canada]Source :
- [ 0014-2999 ]
English descriptors
- KwdEn :
- Adenosine (metabolism), Animals, Carrier Proteins (physiology), Cells, Cultured, Cricetinae, Dose-Response Relationship, Drug, Male, Membrane Proteins (physiology), Mesocricetus, Muscle, Smooth (metabolism), Nucleoside Transport Proteins, Stereoisomerism, Thioinosine (analogs & derivatives), Thioinosine (pharmacology), Tritium.
- MESH :
- chemical , analogs & derivatives : Thioinosine.
- chemical , metabolism : Adenosine.
- chemical , pharmacology : Thioinosine.
- chemical , physiology : Carrier Proteins, Membrane Proteins.
- metabolism : Muscle, Smooth.
- Animals, Cells, Cultured, Cricetinae, Dose-Response Relationship, Drug, Male, Mesocricetus, Nucleoside Transport Proteins, Stereoisomerism, Tritium.
Abstract
[3H]l-Adenosine, an enantiomer of the physiological d-adenosine, was shown previously to be taken up and released, at least in part, through nucleoside transporters in rat brain preparations. In the present study, we used clonal smooth muscle DDT1 MF-2 cells that contain almost exclusively equilibrative inhibitor-sensitive (es) nucleoside transporters to test the hypothesis that l-adenosine is a permeant for these bidirectional nucleoside transporters. DDT1 MF-2 cells accumulated approximately 3 times more [3H]d- than [3H]l-adenosine; 10 μM nitrobenzylthioinosine significantly (P < 0.01) inhibited the accumulation of [3H]d-adenosine by 86% and of [3H]l-adenosine by 63%. The IC50 values for the nitrobenzylthioinosine-sensitive portions of [3H]l- and [3H]d-adenosine accumulation were 1.6 and 2.0 nM, respectively. [3H]d-Adenosine accumulation was significantly (P < 0.05) inhibited by up to 72% with l-adenosine and [3H]l-adenosine accumulation was significantly (P < 0.01) inhibited by up to 52% with d-adenosine. Release of accumulated [3H]l-adenosine was temperature- and time-dependent, and was significantly (P < 0.05) reduced by 47% with dipyridamole, 39% with dilazep, and 45% with nitrobenzylthioinosine; the apparent IC50 value for nitrobenzylthioinosine was < 1 nM. These data indicate that a significant proportion of [3H]l-adenosine uptake and release in DDT1 MF-2 cells is mediated by es nucleoside transporters.
Url:
DOI: 10.1016/S0014-2999(96)00720-0
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000303
- to stream Istex, to step Curation: 000303
- to stream Istex, to step Checkpoint: 001716
- to stream Main, to step Merge: 004396
- to stream PubMed, to step Corpus: 001852
- to stream PubMed, to step Curation: 001852
- to stream PubMed, to step Checkpoint: 001852
- to stream Ncbi, to step Merge: 002571
- to stream Ncbi, to step Curation: 002571
- to stream Ncbi, to step Checkpoint: 002571
- to stream Main, to step Merge: 004357
- to stream Main, to step Curation: 003D07
Le document en format XML
<record><TEI wicri:istexFullTextTei="no"><teiHeader><fileDesc><titleStmt><title>Nucleoside transporter-mediated uptake and release of [3H]l-adenosine in DDT1 MF-2 smooth muscle cells</title><author><name sortKey="Foga, Irene O" sort="Foga, Irene O" uniqKey="Foga I" first="Irene O." last="Foga">Irene O. Foga</name></author><author><name sortKey="Geiger, Jonathan D" sort="Geiger, Jonathan D" uniqKey="Geiger J" first="Jonathan D." last="Geiger">Jonathan D. Geiger</name></author><author><name sortKey="Parkinson, Fiona E" sort="Parkinson, Fiona E" uniqKey="Parkinson F" first="Fiona E." last="Parkinson">Fiona E. Parkinson</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:16D07180A97CB1F858DF8D7C42FD5BD9545E7348</idno><date when="1996" year="1996">1996</date><idno type="doi">10.1016/S0014-2999(96)00720-0</idno><idno type="url">https://api-v5.istex.fr/document/16D07180A97CB1F858DF8D7C42FD5BD9545E7348/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000303</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000303</idno><idno type="wicri:Area/Istex/Curation">000303</idno><idno type="wicri:Area/Istex/Checkpoint">001716</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001716</idno><idno type="wicri:doubleKey">0014-2999:1996:Foga I:nucleoside:transporter:mediated</idno><idno type="wicri:Area/Main/Merge">004396</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:9016938</idno><idno type="wicri:Area/PubMed/Corpus">001852</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001852</idno><idno type="wicri:Area/PubMed/Curation">001852</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001852</idno><idno type="wicri:Area/PubMed/Checkpoint">001852</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001852</idno><idno type="wicri:Area/Ncbi/Merge">002571</idno><idno type="wicri:Area/Ncbi/Curation">002571</idno><idno type="wicri:Area/Ncbi/Checkpoint">002571</idno><idno type="wicri:doubleKey">0014-2999:1996:Foga I:nucleoside:transporter:mediated</idno><idno type="wicri:Area/Main/Merge">004357</idno><idno type="wicri:Area/Main/Curation">003D07</idno><idno type="wicri:Area/Main/Exploration">003D07</idno></publicationStmt><sourceDesc><biblStruct><analytic><author><name sortKey="Foga, Irene O" sort="Foga, Irene O" uniqKey="Foga I" first="Irene O." last="Foga">Irene O. Foga</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pharmacology and Therapeutics, University of Manitoba, 770 Bannatyne Avenue, Winnipeg, R3E 0W3</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation></author><author><name sortKey="Geiger, Jonathan D" sort="Geiger, Jonathan D" uniqKey="Geiger J" first="Jonathan D." last="Geiger">Jonathan D. Geiger</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pharmacology and Therapeutics, University of Manitoba, 770 Bannatyne Avenue, Winnipeg, R3E 0W3</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation></author><author><name sortKey="Parkinson, Fiona E" sort="Parkinson, Fiona E" uniqKey="Parkinson F" first="Fiona E." last="Parkinson">Fiona E. Parkinson</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pharmacology and Therapeutics, University of Manitoba, 770 Bannatyne Avenue, Winnipeg, R3E 0W3</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation></author></analytic><series><idno type="ISSN">0014-2999</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0014-2999</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine (metabolism)</term><term>Animals</term><term>Carrier Proteins (physiology)</term><term>Cells, Cultured</term><term>Cricetinae</term><term>Dose-Response Relationship, Drug</term><term>Male</term><term>Membrane Proteins (physiology)</term><term>Mesocricetus</term><term>Muscle, Smooth (metabolism)</term><term>Nucleoside Transport Proteins</term><term>Stereoisomerism</term><term>Thioinosine (analogs & derivatives)</term><term>Thioinosine (pharmacology)</term><term>Tritium</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Thioinosine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Adenosine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Thioinosine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Carrier Proteins</term><term>Membrane Proteins</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Muscle, Smooth</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cells, Cultured</term><term>Cricetinae</term><term>Dose-Response Relationship, Drug</term><term>Male</term><term>Mesocricetus</term><term>Nucleoside Transport Proteins</term><term>Stereoisomerism</term><term>Tritium</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">[3H]l-Adenosine, an enantiomer of the physiological d-adenosine, was shown previously to be taken up and released, at least in part, through nucleoside transporters in rat brain preparations. In the present study, we used clonal smooth muscle DDT1 MF-2 cells that contain almost exclusively equilibrative inhibitor-sensitive (es) nucleoside transporters to test the hypothesis that l-adenosine is a permeant for these bidirectional nucleoside transporters. DDT1 MF-2 cells accumulated approximately 3 times more [3H]d- than [3H]l-adenosine; 10 μM nitrobenzylthioinosine significantly (P < 0.01) inhibited the accumulation of [3H]d-adenosine by 86% and of [3H]l-adenosine by 63%. The IC50 values for the nitrobenzylthioinosine-sensitive portions of [3H]l- and [3H]d-adenosine accumulation were 1.6 and 2.0 nM, respectively. [3H]d-Adenosine accumulation was significantly (P < 0.05) inhibited by up to 72% with l-adenosine and [3H]l-adenosine accumulation was significantly (P < 0.01) inhibited by up to 52% with d-adenosine. Release of accumulated [3H]l-adenosine was temperature- and time-dependent, and was significantly (P < 0.05) reduced by 47% with dipyridamole, 39% with dilazep, and 45% with nitrobenzylthioinosine; the apparent IC50 value for nitrobenzylthioinosine was < 1 nM. These data indicate that a significant proportion of [3H]l-adenosine uptake and release in DDT1 MF-2 cells is mediated by es nucleoside transporters.</div></front></TEI><affiliations><list><country><li>Canada</li></country><region><li>Manitoba</li></region><settlement><li>Winnipeg</li></settlement><orgName><li>Université du Manitoba</li></orgName></list><tree><country name="Canada"><region name="Manitoba"><name sortKey="Foga, Irene O" sort="Foga, Irene O" uniqKey="Foga I" first="Irene O." last="Foga">Irene O. Foga</name></region><name sortKey="Geiger, Jonathan D" sort="Geiger, Jonathan D" uniqKey="Geiger J" first="Jonathan D." last="Geiger">Jonathan D. Geiger</name><name sortKey="Parkinson, Fiona E" sort="Parkinson, Fiona E" uniqKey="Parkinson F" first="Fiona E." last="Parkinson">Fiona E. Parkinson</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003D07 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003D07 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:16D07180A97CB1F858DF8D7C42FD5BD9545E7348
|texte= Nucleoside transporter-mediated uptake and release of [3H]l-adenosine in DDT1 MF-2 smooth muscle cells
}}
| This area was generated with Dilib version V0.6.29. |  |